https://www.prnewswire.com/news-releases/optimer-pharmaceuticals-and-astrazeneca-collaborate-to-commercialize-fidaxomicin-for-clostridium-difficile-infection-in-latin-america-181819621.html
/PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca to commercialize...
optimer pharmaceuticalsastrazenecacollaboratecommercializefidaxomicin